Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nidlegy neoadjuvant therapy in Stage III B/C melanoma
NCT02938299Phase 3Active, not recruiting
- Sponsor
- Philogen
- Start
- Jul 2016
- Primary completion
- Oct 2024
- Modality
- Antibody Fragments, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of Nidlegy in melanoma (2 arms), sponsored by Philogen. Primary endpoint: Recurrence-free survival rate at 1 year. Started Jul 2016; status: active, not recruiting.
02
Drugs
Nidlegy
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02938299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02938299.